Alpha Cognition Inc. Overview
Pro stress-test →Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's Disease and Cognitive Impairment with Traumatic Brain Injury (TBI). ZUNVEYL® is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects.
Strategic Profile
Pro stress-test →In Q1 2026, Alpha Cognition reported ZUNVEYL net product revenue of $3.5 million, up 40% sequentially, with cumulative launch revenue of $10.3 million. The company currently has no debt on its balance sheet, which is rare for a loss-making biotech, operating purely on its equity investment. The company targets operating profitability in 2027, has Medicare Part D contracts covering about 45 million lives, and expects BEACON top-line data in early Q3 2026.
Competitive Landscape
Pro stress-test →ZUNVEYL is differentiated from donepezil and rivastigmine as a next-generation acetylcholinesterase inhibitor that binds neuronal nicotinic receptors, particularly the alpha-7 subtype, known to have positive effects on cognition. Alpha Cognition competes against established Alzheimer's treatments (donepezil, rivastigmine, memantine) and emerging biotech therapies targeting cognitive decline, with competitive advantages rooted in novel mechanism and favorable tolerability profile.
Industry Context
Alpha Cognition Inc. operates in Neurodegenerative disease therapeutics.
Key facts
Founded: 2000 · Headquarters: Vancouver, Canada · Employees: Not disclosed · Revenue: $4.6M for 2025; estimated $223M-$231M for 2025 (analyst consensus); $515M-$599M for 2026 (analyst consensus) · Market cap: $158M (July 2026)